Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

Bicyclos Breaking down barriers to foster new Cyclodextrin-based applications for healthcare by implementing sustainable design principles

Coordinator
Consiglio Nazionale Delle Ricerche, Italy
Runs
1 September 2023 to 31 August 2027
Status
Running
EU funding
€1.3m
Total cost
—
Partners
13 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101130235

What the project is doing

In the project's own words, from its summary on CORDIS.

Cyclodextrins (CD) have already gained several market applications as excipients in drug and vaccine formulations. They are very appealing platforms for the development of therapeutic applications and new CD-based systems are continuously proposed. In this frame easily prepared CD polymers frequently outstand the performance of the corresponding CD monomers. Nevertheless, application of new CDs as drug or delivery system in the clinics does not take off in spite of their most promising features.

This is mainly due to a lack in transfer of knowledge between the academic world and the private sector focusing on CD for biomedical applications. The consortium formed by a multidisciplinary team, all with interest in CD and nanomedicines, accepts the challenge to bring CD-based systems closer to clinical application. To reach this goal an intense secondment scheme for young and experienced researchers is envisaged with activities that are all contributing to the scientific pursuit of CD progress.

Activities focus on the design of sustainable syntheses of new CD, full characterization of new functionalized CD, the preparation of CD delivery systems for therapeutics and the study of the biological behavior of the CD-based nanomedicines in 2D and 3D models. The teams will embrace, already from the design stage, the production standards affording compliance with GMP for medicine development and prefer strategic approaches in line with the EU 2030 Agenda for Sustainable Development.

The consortium features 11 partners with 4 coming from the private sector. Two of them hold concrete interest in the exploitation of research results as their core business focuses on CD for biomedical applications. This intersectoral and interdisciplinary team will foster new applications of CD-based systems as drugs, delivery systems or sensors and participating staff will enrich their profile with scientific and soft skills that are easily transferred to other research topics or sectors.

Topics

Who is involved

OrganisationCityCountryRole
Consiglio Nazionale Delle RicercheRomaItalyCoordinator
Universidad De Buenos AiresBuenos AiresARAssociatedpartner
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Fundacion De Investigacion De La Universidad De SevillaSevillaSpainAssociatedpartner
Md Use Innovations SLSantiago De CompostelaSpainParticipant
Universidad De SevillaSevillaSpainParticipant
Carbohyde Zartkoruen Mukodo ReszvenytarsasagBudapestHungaryParticipant
Eotvos Lorand TudomanyegyetemBudapestHungaryParticipant
Technological University DublinDublinIrelandParticipant
Celldynamics IsrlImolaItalyParticipant
Hacettepe UniversitesiCankaya AnkaraTürkiyeParticipant
Cyclarity Therapeutics IncNovatoUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI